Saturday, 22 July 2017 - 14:18

Top stories

News of the week

Sanofi signs new research agreement for inflammatory/autoimmune disorders

After announcing it acquired Protein Sciences on July 12, Sanofi informed yesterday about a new cooperation agreement which caused shares to further rise (Wall Street) by 2.7%. The agreement was concluded with Belgium-based Ablynx, a biotech company focused on special…

Approvals

Procedures / New drug and device authorizations / Recommendations

Gilead to strengthen hepatitis C portfolio with Vosevi

Gilead strengthens its position in the hepatitis C treatment business by introducing a new product into its portfolio. The California-based group announced yesterday that FDA approved Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg tablet) for the 12-week treatment of…

Companies

Healthcare market news

Gilead to strengthen hepatitis C portfolio with Vosevi

Gilead strengthens its position in the hepatitis C treatment business by introducing a new product into its portfolio. The California-based group announced yesterday that FDA approved Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg tablet) for the 12-week treatment of…

Chemistry

Market and Technology

Ton Büchner, AkzoNobel CEO, steps down

Ton Büchner, CEO of the Netherlands-based chemical group AkzoNobel, resigned today due to health reasons. The news surprised the financial community, which would have never expected Büchner, the author of AkzoNobel’s resistance strategy to US’ PPG takeover attempt, to leave….

M&A

Mergers & Acquisitions

New €4.1bn offer for Stada by Bain & Cinven consortium

Stada received this evening a new offer by the consortium created by private equities Cinven and Bain Capital. The consortium increased its previous offer to €4.1bn – €66.25 per share. The new offer is now subject to approval by shareholders,…

Nutraceuticals

Food supplements

India is the new frontier of nutraceutical industry

The nutraceutical market will continue its global growth in the years to come. According to recent studies, the business will reach $241bn before 2019, with a 6.9% growth rate (2014-2019 CAGR). The fastest-growing area will be India, whose nutraceutical market…

Pathology

Latest developments

Gilead to strengthen hepatitis C portfolio with Vosevi

Gilead strengthens its position in the hepatitis C treatment business by introducing a new product into its portfolio. The California-based group announced yesterday that FDA approved Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg tablet) for the 12-week treatment of…

Safety

News on Product Safety

Biogen/AbbVie’s Zinbryta under review by PRAC

EMA PRAC (Pharmacovigilance Risk Assessment Committee) launched a review of Biogen/AbbVie’s Zinbryta (daclizumab). The product is intended to treat adult patients with relapsing forms of multiple sclerosis. The review follows the sudden death from liver failure of a patient who…

Trials

Preclinical Trials / Clinical Trials / Epidemiology

Roche announces results from two clinical trials with emicizumab in Hemophilia A patients

The prestigious New England Journal of Medicine published today results from the Phase III HAVEN 1 clinical trial, conducted with the investigational drug emicizumab prophylaxis, administered subcutaneously in adult patients with hemophilia. Emicizumab, a treatment developed by Switzerland-based Roche, met…